<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704636</url>
  </required_header>
  <id_info>
    <org_study_id>TP-19457</org_study_id>
    <nct_id>NCT03704636</nct_id>
  </id_info>
  <brief_title>Desaturation Validation of INVSENSOR00028</brief_title>
  <official_title>Desaturation Validation of INVSENSOR00028</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masimo Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masimo Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to measure the trending accuracy of a noninvasive regional oximetry&#xD;
      measurement of somatic oxygen saturation. Two large sensors (adult sensors) will be placed on&#xD;
      the subject's forehead. Two investigational sensors (INVSENSOR00028) will be placed on the&#xD;
      forearm of the volunteer. The values obtained by the INVSENSOR00028 will be compared to the&#xD;
      reference value calculated from the arterial and venous blood measurements. Data will be&#xD;
      collected from healthy adult subjects while undergoing a desaturation procedure wherein the&#xD;
      concentration of oxygen inhaled is slowly reduced until the subject's arterial oxygen&#xD;
      saturation is approximately 70%, while blood samples are drawn at prespecified reference&#xD;
      points. The subject will then be returned to inhaling room air.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Actual">October 24, 2018</completion_date>
  <primary_completion_date type="Actual">October 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen Saturation (rSO2) Accuracy of Sensor</measure>
    <time_frame>1-5 hours</time_frame>
    <description>The Trending accuracy of the INVSENSOR00028 will be evaluated relative to the reference value calculated from the arterial and venous blood measurements.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INVSENSOR00028</intervention_name>
    <description>Noninvasive pulse oximeter sensor</description>
    <arm_group_label>Test Subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject weighs a minimum of 110 lbs and no more than 250 lbs unless subject is over 6&#xD;
             feet tall.&#xD;
&#xD;
          -  Hemoglobin value is greater than or equal to 11 g/dL.&#xD;
&#xD;
          -  Baseline heart rate ≥ 45 bpm and ≤ 85 bpm.&#xD;
&#xD;
          -  CO value ≤ 2.0% FCOHb&#xD;
&#xD;
          -  Subject has a physical status of ASA I or II (American Society of Anesthesiology Class&#xD;
             I; Healthy subjects without any systemic disease at all. American Society of&#xD;
             Anesthesiology Class II; subjects with mild systemic disease) as it applies to the&#xD;
             systemic disease portion of the classification.&#xD;
&#xD;
          -  Systolic Blood Pressure ≤ 140 mmHg and Diastolic Blood Pressure ≤ 90 mmHg.&#xD;
&#xD;
          -  Subject is able to read and communicate in English and understands the study and risks&#xD;
             involved.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant.&#xD;
&#xD;
          -  Subject smokes (smoking includes e-cigarette use).&#xD;
&#xD;
          -  Subject has a BMI &gt; 35 and has been classified as morbidly obese or at an increased&#xD;
             risk for participation by a medical professional.&#xD;
&#xD;
          -  Subject has a history of fainting (vasovagal), blacking out or losing consciousness&#xD;
             during or after a blood draw.&#xD;
&#xD;
          -  Subject has open wounds, inflamed tattoos or piercings, visible healing wounds.&#xD;
&#xD;
          -  Subject experiences frequent or severe headaches and/or migraine headaches.&#xD;
&#xD;
          -  Subject has known drug or alcohol abuse and/or use of recreational drugs.&#xD;
&#xD;
          -  Subject has experienced a concussion or head injury with loss of consciousness within&#xD;
             the last year.&#xD;
&#xD;
          -  Subject has any chronic bleeding disorders (i.e. hemophilia).&#xD;
&#xD;
          -  Subject has any history of a stroke, myocardial infarction, seizures or heart attack.&#xD;
&#xD;
          -  Subject has any cancer or history of cancer (not including skin cancer).&#xD;
&#xD;
          -  Subject has a chronic neurological disease (i.e. multiple sclerosis, Huntington's&#xD;
             Disease).&#xD;
&#xD;
          -  Subject has any cardiac dysrhythmia(s) (i.e. atrial fibrillation) and has not received&#xD;
             clearance by their physician to participate.&#xD;
&#xD;
          -  Subject has a known neurological and/or psychiatric disorder (i.e. schizophrenia,&#xD;
             bipolar disorder) that interferes with the subject's level of consciousness.&#xD;
&#xD;
          -  Subject has any medical condition which in the judgment of the investigator and/or&#xD;
             medical staff, renders them ineligible for participation in this study (Discretion of&#xD;
             investigator).&#xD;
&#xD;
          -  Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome.&#xD;
&#xD;
          -  Subject who has taken anticoagulant medication within the last 30 days.&#xD;
&#xD;
          -  Subject has taken opioid pain medication within 24 hours of start of study.&#xD;
&#xD;
          -  Subject has any type of infectious disease (i.e. Hepatitis, HIV, Tuberculosis, Flu,&#xD;
             Malaria, Measles, etc.).&#xD;
&#xD;
          -  Subject is taking medications known to treat any type of infectious disease.&#xD;
&#xD;
          -  Subject has either signs or history of peripheral ischemia.&#xD;
&#xD;
          -  Subject has had invasive surgery within the past year- including but not limited to&#xD;
             major dental surgery, gallbladder, heart, appendix, major fracture repairs (involving&#xD;
             plates/ screws), jaw surgery, urinary tract surgery, plastic surgery, major ENT&#xD;
             surgery, joint replacement or gynecological surgeries, heart surgery or thoracic&#xD;
             surgery.&#xD;
&#xD;
          -  Subject has donated blood within the past 30 days.&#xD;
&#xD;
          -  Subject has symptoms of congestion, head colds, flu or other illnesses.&#xD;
&#xD;
          -  Subject experiences claustrophobia or has generalized anxiety disorder.&#xD;
&#xD;
          -  Subject has been in severe car accident(s) or a similar type of accident(s) requiring&#xD;
             hospitalization within the last 12 months.&#xD;
&#xD;
          -  Subject has chronic unresolved asthma, lung disease or respiratory disease.&#xD;
&#xD;
          -  Subject is allergic to lidocaine, latex, adhesives, or plastic.&#xD;
&#xD;
          -  Subject has heart conditions, insulin-dependent diabetes or uncontrolled hypertension.&#xD;
&#xD;
          -  Subject has given vaginal delivery, had a pregnancy terminated, a miscarriage with&#xD;
             hospitalization, or had a C-section within the last 6 months.&#xD;
&#xD;
          -  Subject intends to participate in any heavy lifting, repetitive movement of their&#xD;
             wrist (including riding a motorcycle) or exercise (working out, riding a bike, riding&#xD;
             a skate board etc.), or any activity that will put additional stress on the wrist&#xD;
             within 24 hours of the study.&#xD;
&#xD;
          -  Discretion of investigator/study staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Masimo Corporation</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <results_first_submitted>June 24, 2021</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <disposition_first_submitted>October 16, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 16, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 15, 2021</disposition_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03704636/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 46 enrolled participants, 23 met inclusion criteria and proceeded to the study. The remainder of the enrolled participants include screen failures and subjects that did not proceed due to time constraints.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test Subject</title>
          <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.&#xD;
INVSENSOR00028: Noninvasive pulse oximeter sensor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inadequate Venous Flow</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Subject</title>
          <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.&#xD;
INVSENSOR00028: Noninvasive pulse oximeter sensor</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 18 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 to 50 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 50 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oxygen Saturation (rSO2) Accuracy of Sensor</title>
        <description>The Trending accuracy of the INVSENSOR00028 will be evaluated relative to the reference value calculated from the arterial and venous blood measurements.</description>
        <time_frame>1-5 hours</time_frame>
        <population>There is no apparent trend in either the Brachial or Flexor RSO2 data with respect to the control. Since there is no measurable trend, a numerical value for Trending Accuracy (as defined in the protocol) cannot be accurately determined.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Subject</title>
            <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.&#xD;
INVSENSOR00028: Noninvasive pulse oximeter sensor</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation (rSO2) Accuracy of Sensor</title>
          <description>The Trending accuracy of the INVSENSOR00028 will be evaluated relative to the reference value calculated from the arterial and venous blood measurements.</description>
          <population>There is no apparent trend in either the Brachial or Flexor RSO2 data with respect to the control. Since there is no measurable trend, a numerical value for Trending Accuracy (as defined in the protocol) cannot be accurately determined.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 to 5 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Subject</title>
          <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.&#xD;
INVSENSOR00028: Noninvasive pulse oximeter sensor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sensitivity at arterial line site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chelsea Frank</name_or_title>
      <organization>Masimo Corporation</organization>
      <phone>949-297-7000</phone>
      <email>studies@masimo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

